Insight Molecular Diagnostics Profit Margin

Insight Molecular Diagnostics (IMDX) currently reports a profit margin of -2955.63% as of June 2026. That compares with -1489.71% in the prior-year period — down 98.4% year over year. That is below the Technology sector average of 35.92%. Use the charts on this page to explore Insight Molecular Diagnostics's profit margin history and peer comparisons.

Insight Molecular Diagnostics's profit margin decreased from -1489.71% to -2955.63% — a 98.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Insight Molecular Diagnostics's profit margin of -2955.63% is lower than the Technology sector average of 35.92%. That is roughly 8329.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Insight Molecular Diagnostics's current -2955.63% should be judged against Technology norms (sector average: 35.92%) and against IMDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2955.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 35.92%. From there, open related valuation or income-statement pages for Insight Molecular Diagnostics, and consider following IMDX for alerts when major investors trade the stock.